Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Experts from AIIMS Delhi emphasised obesity’s harmful health effects and the need for preventive actions, supporting Prime ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

"The increasing prevalence of cardiovascular conditions in younger people has many factors. Key contributors include obesity, ...

Spices alone cannot directly lead to weight loss, but some have properties that may help support your weight management plan. Here's which spices to add to your diet.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Central obesity measures of waist circumference and waist-to-hip ratio appear to be more accurate and consistent indicators of colorectal cancer incidence compared with BMI, according to a study ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...